Home   |   Register   |   Sponsor   |   FAQ   |   Contact


Register for the Biomarker World Congress and save 20% off Biomarker Web Symposia!


Why attend CHI’s Biomarker Web Symposia:

  • Content: Learn about cutting-edge biomarker research; build on the solid 7-year track-record of the Biomarker Series of conferences. Access timely topics, international thought-leaders and interactive discussions.
  • Convenience: Join the Web Symposia for a 2-3 hour time commitment from the comfort and convenience of your office or home. All you need is phone and internet; and the entire content will be delivered right to your desktop.
  • Savings: No hassles or expenses of travel, no time away from the office. Your whole team can attend a Web Symposium from a conference room. Register for multiple Web Symposia and save!
  • Flexibility: Choose from a broad offering to customize your Web Symposia package or register for the whole Series and share with your group. If you have a scheduling conflict, you can download the Web Symposium on-demand at your convenience.


Biomarker Web Symposia Schedule* for Spring 2009

*Schedule subject to change. Schedules are posted in Eastern Standard Time (EST). Additional dates and speakers to be announced.

Stay tuned for new topics!

Featured Speakers Spring 2009

  • Josip Blonder, M.D., Senior Research Scientist, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick Inc., NCI-Frederick
  • John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.
  • David Brown, Ph.D., Director, Research and Development, Asuragen, Inc.
  • George A. Calin, M.D., Ph.D., Associate Professor, Experimental Therapeutics & Cancer Genetics, The University of Texas, M.D. Anderson Cancer
  • Walter P. Carney, Ph.D., Head, Oncogene Science, Siemens Healthcare Dx
  • Mark R. Chance, Ph.D., Director, Center for Proteomics & Synchrotron Biosciences, Physiology & Biophysics, School of Medicine, Case Western Reserve University
  • Giora Z. Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research Laboratories
  • Martin Fleisher, Ph.D., Chair, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center
  • Richard A. Frank, M.D., Ph.D., FFPM (RCP), Vice President, Global Medical Affairs and Clinical Strategy, GE Healthcare
  • Herbert A. Fritsche, Ph.D., Professor and Chief, Clinical Chemistry, Department of Laboratory Medicine, The University of Texas, M.D. Anderson Cancer Center
  • Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology/Office of Translational Sciences/ Center for Drug Evaluation and Research, U.S. Food and Drug Administration
  • Samir M. Hanash, M.D., Ph.D., Program Head, Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center
  • J. Milburn Jessup, M.D., Chief, Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD/National Cancer Institute
  • Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research Laboratory, Department of Pathology,Stony Brook University Medical Center
  • Bing Kuang, Ph.D., Principal Scientist, Translational Research, PDM, PGRD, Pfizer, Inc.
  • Bruce H. Littman, M.D., President, Translational Medicine Associates LLC
  • Ruth E. March, Ph.D., Lead, Personalized Healthcare Team, AstraZeneca Pharmaceuticals
  • Christopher-Paul Milne, D.V.M., M.P.H., J.D., Associate Director, Tufts Center for the Study of Drug Development, Tufts University
  • Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
  • Shannon Payne, Ph.D., Senior Scientist, Epigenomics, Inc.
  • Emanuel F. Petricoin III, Ph.D., Professor, Life Sciences & Company Director, Applied Proteomics & Molecular Medicine, George Mason University
  • Reena Philip, Ph.D., Scientific Reviewer, DIHD/OIVD/CDRH/FDA
  • Paul W. Rhyne, Ph.D., Associate Director, Bioanalytical Sciences, Bristol Myers Squibb Co.
  • Frank Richardson, Ph.D., Senior Director, Safety Assessment & Molecular Markers, OSI Pharmaceuticals
  • Karin D. Rodland, Ph.D., Science Lead, NIH Programs, Biological Sciences, Pacific Northwest National Laboratory
  • Anderson Ryan, Ph.D., Principle Translational Scientist, Cancer BioScience, Global Discovery Science Lead and Translational Science Strategist for ZACTIMA (vandetanib) project, AstraZeneca
  • Jeffrey Shuster, Ph.D., Director, Diagnostics Development, Metabolon, Inc.
  • Georgina Speake, Ph.D., Translational Science Strategist, Cancer BioScience, Global Discovery Science Lead and Translational Science Strategist for IRESSA (gefitinib) project, AstraZeneca
  • David F. Stroncek, M.D., Chief, Cell Processing, National Institutes of Health Clinical Center
  • Anna Szafranska-Schwarzbach, Ph.D., CLIA Laboratory Supervisor, Pharmacogenomics Services, Asuragen, Inc.
  • Ruth A. VanBogelen, Ph.D., Director, Biomarkers & Proteomics, NextGen Sciences, Inc.

 

For more information, please contact:
Julia Boguslavsky, Executive Director, Conferences
E-mail: juliab@healthtech.com

For sponsorship information, please contact:
Ilana Quigley, Business Development
Phone: 781-972-5457; E-mail: iquigley@healthtech.com